Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
about
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells.HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.Haematological malignancies: at the forefront of immunotherapeutic innovation.Upregulation of hyaluronan-mediated motility receptor in hepatocellular carcinoma predicts poor survival.Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.PRAME expression in hairy cell leukemia.Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experienceAdoptive T-cell therapy for B-cell malignancies.ZRF1: a novel epigenetic regulator of stem cell identity and cancer.Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias - assessment of clinical outcome, post induction, end of treatment and minimal residual disease
P2860
Q33718767-7A824196-286B-4E0E-93FB-FCF2166BEA66Q33760690-DAA87CCD-6434-4CDD-BD5A-D1709CE190F4Q34985471-6D790991-C460-47DF-BD08-4D4F3D2DC4B2Q35489417-A4707BB5-560C-4411-AEF7-1E33DCD4F7FFQ35880618-EF1E5C69-A820-4F08-8696-A2061F10F080Q36334849-E75CA766-D514-4846-BC91-F496F3B6979AQ36662079-EA3F2DE7-9E5B-45E6-8A1A-B6B14976AF23Q36748859-9FFAD825-D608-48B2-A397-BDCA6416CA06Q37268297-2130BEEA-1D52-488F-9522-8334ADC0B2C9Q37772085-8F660CD8-6037-45BA-85BD-479FC43481A1Q37810116-082DB258-1D21-40AD-8644-2B4C96B97B2EQ38349238-838C0F95-8ED1-4EF5-9A08-8706E9563078Q39092611-695F7995-F8C4-4B64-9197-32B184448480Q39243052-3C7CF007-99AC-424E-9AA9-987A4A7D3BD1Q39831942-148A7E59-314E-448A-B410-E747FB3D2883Q47143616-8F0CC2A3-819D-487A-8996-46C998A76C4DQ48375750-63A7DC93-432D-497E-94B4-2A0F0876758DQ55480165-C1365916-6826-4E9D-9AD5-87CA89D8191FQ58124882-E1D187FC-DF24-4D57-8CAE-ACC3EAFAA531
P2860
Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Expression of RHAMM/CD168 and ...... chronic lymphocytic leukemia.
@ast
Expression of RHAMM/CD168 and ...... chronic lymphocytic leukemia.
@en
type
label
Expression of RHAMM/CD168 and ...... chronic lymphocytic leukemia.
@ast
Expression of RHAMM/CD168 and ...... chronic lymphocytic leukemia.
@en
prefLabel
Expression of RHAMM/CD168 and ...... chronic lymphocytic leukemia.
@ast
Expression of RHAMM/CD168 and ...... chronic lymphocytic leukemia.
@en
P2093
P1476
Expression of RHAMM/CD168 and ...... l chronic lymphocytic leukemia
@en
P2093
A Bojarska-Junak
A Dmoszynska
J Rolinski
K Giannopoulos
P304
P50
P577
2006-07-01T00:00:00Z